home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Tumour Suppressor Linked To Heart Failure?

  March, 8 2007 8:04
your information resource in human molecular genetics
Inhibition of angiogenesis by the tumour suppressor protein p53 may have a critical role in the progression of cardiac hypertrophy to cardiac failure, a paper published online by Nature suggests. Targeting this process may prove therapeutically useful.

When the heart struggles to pump blood around the body, it can compensate by becoming enlarged (hypertrophy). But prolonged cardiac hypertrophy can be fatal and lead to heart failure. Issei Komuro and colleagues studied a mouse model of cardiac hypertrophy. As the animals' hearts became enlarged, new blood vessels were seen to grow, supporting cardiac hypertrophy. But after about two weeks, p53 levels increased, angiogenesis was inhibited and the mice progressed to cardiac failure. The absence of p53 or the introduction of factors that stimulate angiogenesis prevented the progression from cardiac hypertrophy to heart failure.


Issei Komuro (Chiba University, Japan)
E-mail: komuro-tky@umin.ac.jp

Abstract available online.

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.